Novartis cast-off gives Pharming a gap-filler
Pharming picks up Novartis’s late-stage PI3K inhibitor and plans to launch it for an ultra-rare disease. How will the competition respond?
Imbruvica resistance provides early but fertile development ground
Targeting a mechanism of resistance to first-generation BTK inhibitors has caught the attention of biotechs like Arqule, which claimed a major success last week.
German Merck boosts autoimmune BTK inhibitor chase
Promising mid-stage data with Merck KGaA’s evobrutinib in multiple sclerosis could help the German group carve out a niche for its BTK inhibitor – unless bigger players…
“Don’t eat me” competition finds Celgene discontinuation hard to digest
Celgene’s surprise termination of a clinical trial makes for a day of soul-searching among other followers of the anti-CD47 approach.
A dose of reality as TG Therapeutics kicks the can down the road
The company’s Unity-CLL trial fails to yield an improvement in overall response, and investors should ask themselves whether the whole study is now doomed.
Slowly, TG investors start to fear the worst
The company’s stock slides 12% on fears that the goalposts in its all-important Unity-CLL trial are being moved.
Seeking alpha in PI3K inhibition
Novartis hails the most advanced alpha-directed PI3K inhibitor after success in breast cancer, but it’s not the only one.
Upcoming events – Crowded markets ahead for TG and Redhill
TG and Redhill are expecting phase III data soon, but both have a fight ahead to make their mark even if their projects succeed.
